Ixazomib (Enleri) dosage, usage and individualized dosage adjustment recommendations

Ixazomib (Ixazomib) is an oral proteasome inhibitor mainly used to treat multiple myeloma. Its standard use is usually in combination with low-dose lenalidomide and dexamethasone. The recommended dose is 4 mg per time, taken orally once a week, followed by a one-week break after three consecutive weeks to complete a 28-day treatment cycle. Patients should take their medications at the same time and as much as possible with food to optimize drug absorption.

During the course of medication, patients need to undergo regular hematology and renal function tests to assess drug tolerance and safety. Doctors often recommend dose adjustments in patients who develop thrombocytopenia, neutropenia, or renal insufficiency. For example, when the platelet count drops significantly, you can consider reducing the dose from 4mg to 3mg or 2.3mg until the blood indicators return to a safe range and then gradually adjust back to the original dose.

For patients with mild to moderate impairment of renal function, Ixazomibusually does not require dose adjustment, but for patients with severe renal impairment or receiving dialysis, it should be used with caution and individualized dose adjustment should be made under the guidance of a physician. In addition, if the patient experiences serious adverse reactions such as peripheral neuropathy, gastrointestinal discomfort, or infection, the drug should be temporarily discontinued and the symptoms treated. After the symptoms are relieved, the dose should be resumed according to the patient's tolerance.

Individualized medication also needs to consider factors such as age, weight, and comorbid diseases. When elderly patients or those with weak constitutions start treatment, doctors may use a lower starting dose and gradually increase it to the standard dose under the premise of safety. At the same time, patients should strictly follow the doctor's instructions and avoid increasing or decreasing the dose on their own to ensure the therapeutic effect and medication safety.

Reference materials:https://www.drugs.com/